Frequency and microbiology of peritonitis and exit-site infection among obese peritoneal dialysis patients

Sharon J Nessim1, Paul Komenda, Claudio Rigatto

  • 1Division of Nephrology, Jewish General Hospital, and McGill University, Montreal, Quebec, Canada. sharon.nessim@mcgill.ca

Abstract

Insights

Obesity in peritoneal dialysis patients did not increase overall peritonitis risk. However, higher body mass index (BMI) was linked to an increased risk of coagulase-negative Staphylococcus (CNS) peritonitis in this Canadian cohort.

Area of Science:

  • Nephrology
  • Infectious Diseases
  • Epidemiology

Background:

  • Limited data exists on obesity as a risk factor for peritonitis and catheter infections in peritoneal dialysis (PD) patients.
  • The microbiology of PD-related infections in high body mass index (BMI) patients is not well understood.

Purpose of the Study:

  • To investigate the relationship between BMI and the risk of PD-related infections, specifically peritonitis and exit-site infection (ESI).
  • To explore if increasing BMI is associated with specific causative organisms in PD infections.

Main Methods:

  • A cohort study of adult PD patients in Manitoba (1997-2007) was conducted.
  • Patients were categorized into BMI quartiles.
  • Multivariate Cox regression analysis was used to assess the independent relationship between BMI and peritonitis or ESI risk, controlling for confounding factors.

Main Results:

  • In the highest BMI quartile, unadjusted analysis showed increased risk for overall peritonitis and gram-positive/coagulase-negative Staphylococcus (CNS) peritonitis.
  • After multivariate adjustment, the overall peritonitis risk associated with BMI disappeared.
  • However, the increased risk of CNS peritonitis persisted in the highest BMI quartile (HR: 1.80; 95% CI: 1.06-3.06).
  • No increased risk of ESI was found in the highest BMI quartile.

Conclusions:

  • Obesity is not associated with an increased risk of overall peritonitis in Canadian PD patients.
  • A higher BMI may be associated with an increased risk of coagulase-negative Staphylococcus (CNS) peritonitis.

Related Concept Videos

Peritoneal Dialysis II: Peritoneal Dialysis Systems and Complications01:25

Peritoneal Dialysis II: Peritoneal Dialysis Systems and Complications

Peritoneal dialysis (PD) is a medical process that removes waste products and excess fluid from the body using the peritoneal membrane as a natural filter.Peritoneal Dialysis MethodsSeveral methods can be used for peritoneal dialysis, including Acute Intermittent Peritoneal Dialysis, Continuous Ambulatory Peritoneal Dialysis, and Automated Peritoneal Dialysis, also known as Continuous Cyclic Peritoneal Dialysis.Acute Intermittent Peritoneal Dialysis (AIPD) is used for patients with uremic...
Peritoneal Dialysis III: Nursing Management01:25

Peritoneal Dialysis III: Nursing Management

Peritoneal dialysis, or PD, utilizes the peritoneal membrane as a filter to eliminate excess fluid and waste products. Effective nursing management is essential for ensuring patient safety, preventing complications, and promoting optimal function of the peritoneal dialysis process.Assessment and MonitoringNurses must thoroughly assess the patient before, during, and after each dialysis session. Regular monitoring includes vital signs, daily weight, fluid intake and output, and laboratory values...
Peritoneal Dialysis I: Introduction and Procedure01:30

Peritoneal Dialysis I: Introduction and Procedure

Peritoneal dialysis (PD) is a procedure that facilitates the exchange of solutes, waste products, electrolytes, and excess fluid between the blood in the peritoneal capillaries and a dialysis solution introduced into the peritoneal cavity.Principles of Peritoneal Dialysis (PD)Diffusion: Waste products such as urea and electrolytes move from high concentrations in the blood to low concentrations in the dialysate across the peritoneal membrane. This mechanism is driven by the concentration...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
Extracorporeal Removal of Drugs: Peritoneal Dialysis and Hemodialysis01:30

Extracorporeal Removal of Drugs: Peritoneal Dialysis and Hemodialysis

Patients with end-stage renal disease (ESRD) or those experiencing drug overdose often require extracorporeal methods to eliminate accumulated drugs and metabolites. Hemoperfusion, hemofiltration, and dialysis are the primary techniques to rapidly remove harmful substances without disrupting the patient's fluid and electrolyte balance. For those with compromised renal function, dosage adjustments of concurrent medications may be necessary during extracorporeal drug removal.Dialysis is a process...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...